Molecular Mediators and Regulators of Glucocorticoid Actions
糖皮质激素作用的分子介质和调节剂
基本信息
- 批准号:8351165
- 负责人:
- 金额:$ 160.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:16p11.23-DimensionalAcetylationAchievementAffectAgonistAllergicAndrogensAnti-Inflammatory AgentsAnti-inflammatoryAttenuatedAutoimmune ProcessBHLH ProteinBedsBindingBiopsyBlood PressureCellsCholesterolCircadian RhythmsCodeCollaborationsComputersCultured CellsDNA SequenceDefectDexamethasoneDiseaseEnzymesExcretory functionFamilyFamily memberFatigueFatty AcidsFatty acid glycerol estersFemaleForce of GravityGenesGeneticGenetic TranscriptionGenomeGlucocorticoid ReceptorGlucocorticoidsGlucoseGoalsGreeceHepaticHourHumanHydrocortisoneImmuneInflammatoryLifeLigand Binding DomainLigandsLipidsLiverLymphocyteLymphoproliferative DisordersLysineManuscriptsMeasuresMediatingMediator of activation proteinMinnesotaMolecularMoonMovementMusMutationNeuraxisNuclear ReceptorsObesityPathologicPatientsPatternPeriodicityPeripheralPhasePhosphoenolpyruvate CarboxylasePhysiologicalPlayPrimary carcinoma of the liver cellsProductionProstaglandinsProteinsRXRRattusReceptor GeneReportingResistanceResponse ElementsRoleSamplingScreening procedureSequence AnalysisSmall Interfering RNAStressSymptomsSyndromeSystemThyroid Hormone ReceptorThyroid HormonesTissuesTransactivationabsorptionbaseboyscomparative genomic hybridizationexomeglucocorticoid-induced orphan receptorglucose metabolismglucose-6-phosphatasehistone acetyltransferasehormone resistancehuman studyinterestlipid metabolismmRNA Expressionmacrophagemedical schoolsmicrodeletionnicotinamide phosphoribosyltransferaseoverexpressionperipheral bloodprobandpromoterprototypereceptorreceptor bindingsteroid hormonesubcutaneoustranscription factor
项目摘要
We investigated the pathophysiologic mechanism of familial/sporadic generalized glucocorticoid resistance syndrome, a prototype of glucocorticoid resistance caused by mutations in the glucocorticoid receptor (GR) gene. We found three new heterozygotic cases with mutations in the GR gene (GR V423A, GR V575G and GR H726R) in collaboration with Dr. Evangelia Charmandari, the Univ of Athens Medical School, Athens, Greece. We are currently analyzing their molecular defects. We have almost completed the computer-based 3-dimensional structural analysis for the ligand-binding domain of all pathologic GR mutations ever reported in addition to these newly identified mutations by using the algorism we established for GR R714Q in the last year.
We also encountered a 7-year boy with mild resistance to glucocorticoids, androgens and thyroid hormones. Array-based comparative genomic hybridization analysis showed that this patient has 1.1 Mb size heterozygotic 16p11.2 microdeletion, while the siRNA-based screening and subsequent molecular analyses revealed that heterozygotic deletion of the ZNF764 gene by his microdeletion is responsive for his multi-hormone resistance, as this protein acts as a common coactivator for the glucocorticoid, androgen and thyroid hormone receptors. This is the first case demonstrating resistance to multiple steroid hormones with identification of the causative gene. We are now preparing a manuscript based on these results.
The liver X receptors (LXRs), which belong to the nuclear receptor superfamily, mediate the biologic actions of various lipids, such as the cholesterol metabolites oxysterols, prostanoids and some fatty acids, by directly binding to these molecules. LXRs exist as two subtypes, LXRα and LXRβ, which display distinct patterns of tissue expression. Once LXRs bind their lipid ligands, they form a heterodimer with the retinoid X receptor (RXR), and stimulate the transcription of an array of genes involved in the absorption, efflux, transport, and excretion of cholesterol and other lipids. LXRs also regulate glucose metabolism by decreasing the expression of its rate-limiting enzymes G6Pase and PEPCK, and have anti-inflammatory activity by repressing a set of inflammatory genes in macrophages and other immune cells. Overexpression/ligand (GW3965) activation of LXRs/RXRs repressed GR-stimulated transactivation of glucocorticoid response element (GRE)-driven promoters in a gene-specific fashion, and activation of LXRs by GW3965 attenuated dexamethasone-stimulated elevation of circulating glucose in rats and suppressed dexamethasone-induced mRNA expression of hepatic glucose-6-phosphatase (G6Pase) in rats, mice and human hepatoma HepG2 cells. Mechanistically, we found that LXRα/RXRα bound GREs and inhibited GR binding to these DNA sequences in a gene-specific fashion. We propose that administration of LXR agonists may be beneficial in glucocorticoid treatment- or stress-associated dysmetabolic states by directly attenuating the transcriptional activity of the GR on glucose and/or lipid metabolism.
Circulating levels of glucocorticoids fluctuate naturally in a circadian fashion, and regulate the transcriptional activity of the GR in target tissues. The basic helix-loop-helix protein CLOCK, a histone acetyltransferase (HAT), and its heterodimer partner BMAL1 are self-oscillating transcription factors that generate circadian rhythms both in the central nervous system and periphery. We previously reported that CLOCK/BMAL1 repressed GR-induced transcriptional activity by acetylating GR at several lysine residues located in its hinge region and by suppressing binding of GR to promoter GREs. These findings indicate that CLOCK/BMAL1 functions as a reverse phase negative regulator of glucocorticoid action in target tissues, possibly by antagonizing the biologic actions of diurnally fluctuating circulating glucocorticoids. We thus performed a human study in which we sampled peripheral blood in the morning and evening from normal subjects, and measured mRNA expression of known glucocorticoid-responsive genes and GR acetylation in circulating lymphocytes. We found that GR was acetylated higher in the morning than in the evening, positively correlating with mRNA expression of CLOCK and BMAL1, while circulating glucocorticoid-stimulated mRNA expression of glucocorticoid responsive genes were repressed by CLOCK/BMAL1 in a gene-specific fashion. These results indicate that the peripheral CLOCK system negatively regulates GR transcriptional activity through acetylation of GR not only in cultured cells but also in humans. In another clinically oriented study in which we measured mRNA expression of 190 GR action-regulating and glucocorticoid-responsive genes in subcutaneous fat biopsied from 25 obese subjects, we found that the morning/evening cortisol ratio, an indicator for the amplitude of circadian rhythmicity of circulating cortisol, negatively correlated with mRNA expression of the nicotinamide phosphoribosyltransferase (NAMPT), which is a rate-limiting enzyme for the production of intracellular NAD+. It is known that NAMPT/NAD+ is necessary for maintaining circadian rhythms of the CLOCK transcriptional system. Our results thus indicate that diurnal fluctuation of circulating glucocorticoids provides negative input to local CLOCK activity.
In connection with our study on circadian rhythm, we found one interesting family with seasonal alteration of circadian rhythmicity in collaboration with Dr. F. Halberg, the Univ. of Minnesota. The proband, 61-year old female, has suffered from an annual cycle of severe fatigue including the inability to get out of bed, which lasts 2-3 months in the summer and the winter. She, however, is free from symptoms with high achievement during the unaffected months between these bad periods. The proposita demonstrated elongation of circadian rhythmicity (24.84 hours) in blood pressure and vigor rates during the affected periods, while she was in normal 24-hour rhythm in the unaffected months. The cycle of 24.84 hours is exactly the double of the tidal cycle, which is hypothesized to come about gravity-changes caused by movement of the moon around the earth. To identify genetic cause(s) of these manifestations, we have started whole exome analysis, sequencing the entire coding region of genome in 3 affected subjects and 5 unaffected members of the family.
我们研究了家族性/散发性广泛性糖皮质激素耐药综合征的病理生理机制,这是由糖皮质激素受体(GR)基因突变引起的糖皮质激素耐药的原型。我们与希腊雅典大学医学院的Evangelia Charmandari博士合作,发现了三例新的GR基因突变的杂合子病例(GR V423A、GR V575G和GR H726R)。我们正在分析它们的分子缺陷。我们使用去年为GR R714Q建立的算法,几乎完成了对所有已报道的病理性GR突变以及这些新发现的突变的配体结合域的计算机三维结构分析。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Tomoshige Kino其他文献
Tomoshige Kino的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Tomoshige Kino', 18)}}的其他基金
Molecular Mediators/Regulators of Glucocorticoid Actions
糖皮质激素作用的分子介质/调节剂
- 批准号:
7209191 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Molecular Mediators and Regulators of Glucocorticoid Actions
糖皮质激素作用的分子介质和调节剂
- 批准号:
7734762 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Molecular Mediators and Regulators of Glucocorticoid Act
糖皮质激素作用的分子介质和调节剂
- 批准号:
7332773 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
下丘脑-垂体-肾上腺的病理生理学
- 批准号:
8941436 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
下丘脑-垂体-肾上腺的病理生理学
- 批准号:
7734695 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Pathophysiology of The Hypothalamic-pituitary-adrenal & Gonadal Axes
下丘脑-垂体-肾上腺的病理生理学
- 批准号:
8351107 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Endocrine-immune-reproductive System Interactions
内分泌-免疫-生殖系统相互作用
- 批准号:
7968513 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Molecular Mediators and Regulators of Glucocorticoid Actions
糖皮质激素作用的分子介质和调节剂
- 批准号:
7968640 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Endocrine-immune-reproductive System Interactions
内分泌-免疫-生殖系统相互作用
- 批准号:
8736815 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
Endocrine-immune-reproductive System Interactions
内分泌-免疫-生殖系统相互作用
- 批准号:
8941435 - 财政年份:
- 资助金额:
$ 160.15万 - 项目类别:
相似海外基金
REU Site: Design, Create, and Innovate 3-Dimensional User Interfaces to Improve Human Sensory and Motor Performance in Virtual Environments (HUMANS MOVE)
REU 网站:设计、创建和创新 3 维用户界面,以提高虚拟环境中的人类感官和运动表现 (HUMANS MOVE)
- 批准号:
2349771 - 财政年份:2024
- 资助金额:
$ 160.15万 - 项目类别:
Standard Grant
CAREER: Atomic-level understanding of stability and transition kinetics of 3-dimensional interfaces under irradiation
职业:对辐照下 3 维界面的稳定性和转变动力学的原子水平理解
- 批准号:
2340085 - 财政年份:2024
- 资助金额:
$ 160.15万 - 项目类别:
Continuing Grant
Artificial fabrication of 3-dimensional noncollinear magnetic order and magnetization manipulation by spin torque
三维非共线磁序的人工制造和自旋转矩磁化操纵
- 批准号:
23H00232 - 财政年份:2023
- 资助金额:
$ 160.15万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Understanding of 3-dimensional seismic behavior of RC frame high-speed railway/highway viaducts using FE analysis
使用有限元分析了解 RC 框架高速铁路/公路高架桥的 3 维抗震性能
- 批准号:
23H01489 - 财政年份:2023
- 资助金额:
$ 160.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Modernization of 3-dimensional printing capabilities at the Aquatic Germplasm and Genetic Resource Center
水产种质和遗传资源中心 3 维打印能力的现代化
- 批准号:
10736961 - 财政年份:2023
- 资助金额:
$ 160.15万 - 项目类别:
The 3-dimensional nest of the honey bee: organization, development, and impact on colony function
蜜蜂的 3 维巢穴:组织、发育及其对蜂群功能的影响
- 批准号:
2216835 - 财政年份:2023
- 资助金额:
$ 160.15万 - 项目类别:
Standard Grant
Research on high-density 3-dimensional polymer optical waveguide device for photonics-electronics convergence
光电子融合高密度三维聚合物光波导器件研究
- 批准号:
23H01882 - 财政年份:2023
- 资助金额:
$ 160.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Scaff-Net: 3 Dimensional multiphoton polymerisation printed scaffolds for medium throughput recording from stem cell derived human cortical networks.
Scaff-Net:3 维多光子聚合打印支架,用于从干细胞衍生的人类皮质网络进行中等通量记录。
- 批准号:
EP/X018385/1 - 财政年份:2023
- 资助金额:
$ 160.15万 - 项目类别:
Research Grant
3-dimensional prompt gamma imaging for online proton beam dose verification
用于在线质子束剂量验证的 3 维瞬发伽马成像
- 批准号:
10635210 - 财政年份:2023
- 资助金额:
$ 160.15万 - 项目类别:
Equipment: MRI: Track 1 Acquisition of a 3-Dimensional Nanolithography Instrument
设备:MRI:轨道 1 获取 3 维纳米光刻仪器
- 批准号:
2320636 - 财政年份:2023
- 资助金额:
$ 160.15万 - 项目类别:
Standard Grant














{{item.name}}会员




